Josef Karner
Overview
Explore the profile of Josef Karner including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
289
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Vockner S, Mattke M, Messner I, Gaisberger C, Zehentmayr F, Ellmauer K, et al.
Cancers (Basel)
. 2025 Feb;
17(3).
PMID: 39941852
Artificial Intelligence (AI) applications are increasingly prevalent in radiotherapy, including commercial software solutions for automatic segmentation of anatomical structures for 3D Computed Tomography (CT). However, their use in intraoperative electron...
2.
Ruznic E, Klebermass M, Zellinger B, Langer B, Grambozov B, Purevdorj A, et al.
J Clin Med
. 2025 Feb;
14(3).
PMID: 39941616
: Current evidence suggests that patients with unresectable non-small cell lung cancer (NSCLC) whose tumours harbour driver mutations do not benefit from immune checkpoint inhibition. Kirsten rat sarcoma virus mutations...
3.
Berchtold J, Winkler C, Karner J, Groher M, Gaisberger C, Sedlmayer F, et al.
Strahlenther Onkol
. 2023 Aug;
200(3):195-201.
PMID: 37626226
Purpose: In ultrahypofractionated radiation concepts, managing of intrafractional motion is mandatory because tighter margins are used and random errors resulting from prostate movement are not averaged out over a large...
4.
Grambozov B, Kalantari F, Beheshti M, Stana M, Karner J, Ruznic E, et al.
Radiother Oncol
. 2023 Jun;
185:109728.
PMID: 37301259
Background And Purpose: Our study aimed to assess whether quantitative pretreatment 18F-FDG-PET/CT parameters could predict prognostic clinical outcome of recurrent NSCLC patients who may benefit from ablative reirradiation. Materials And...
5.
Stana M, Grambozov B, Karner J, Gollner I, Gaisberger C, Ruznic E, et al.
Cancers (Basel)
. 2023 Apr;
15(7).
PMID: 37046627
Introduction: Durvalumab following chemoradiotherapy (CRT) for non-small cell lung cancer stage III has become the standard of care (SoC) in the past few years. With this regimen, 5-year overall survival...
6.
Stana M, Grambozov B, Gaisberger C, Karner J, Ruznic E, Berchtold J, et al.
Diagnostics (Basel)
. 2022 May;
12(5).
PMID: 35626183
Introduction: Curatively intended chemo-radio-immunotherapy for non-small cell lung cancer (NSCLC) stage III may lead to post-therapeutic pulmonary function (PF) impairment. We hypothesized that the decrease in global PF corresponds to...
7.
Grambozov B, Stana M, Kaiser B, Karner J, Gerum S, Ruznic E, et al.
Cancers (Basel)
. 2022 Feb;
14(3).
PMID: 35158841
Introduction: Thoracic re-irradiation for recurrent lung cancer dates back four decades, when the first small series on 29 patients receiving palliative doses was published. With 5-year overall survival rates of...
8.
Zellinger B, Bodenhofer U, Englander I, Kronberger C, Grambozov B, Ruznic E, et al.
Breast Cancer
. 2021 Dec;
29(2):274-286.
PMID: 34865205
Background: MicroRNAs are small non-coding RNAs with pivotal regulatory functions in multiple cellular processes. Their significance as molecular predictors for breast cancer was demonstrated in the past 15 years. The...
9.
Grambozov B, Wass R, Stana M, Gerum S, Karner J, Fastner G, et al.
Thorac Cancer
. 2021 Feb;
12(8):1162-1170.
PMID: 33586228
Background: Given the limited curative treatment options for recurrent lung cancer patients, the aim of our retrospective study was to investigate whether these patients would benefit in terms of overall...
10.
Schorghofer A, Groher M, Karner J, Kopp A, Kametriser G, Kunit T, et al.
Strahlenther Onkol
. 2019 May;
195(10):894-901.
PMID: 31139841
Purpose: Prostate cancer (PCA) is highly heterogeneous in terms of its oncologic outcome. We therefore aimed to tailor radiation treatment to the risk status by using three different hypofractionated radiation...